Weiss Multi-Strategy Advisers’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-35,583	Closed	-$348K	–	579
2015 Q1	$348K	Sell	35,583 -2,750	-7%	-$27K	0.02%	388
2014 Q4	$437K	Buy	38,333 +5,000	+15%	+$54.3K	0.02%	349
2014 Q3	$384K	Buy	33,333 +16,666	+100%	+$255K	0.01%	457
2014 Q2	$324K	Hold	16,667	–	–	0.01%	618
2014 Q1	$299K	Buy	16,667 +6,838	+70%	+$112K	0.01%	820
2013 Q4	$104K	Hold	9,829	–	–	﹤0.01%	942
2013 Q3	$121K	Buy	+9,829	New	+$103K	﹤0.01%	884

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Weiss Multi-Strategy Advisers's CASC Position: Q2 2015 in Review

Weiss Multi-Strategy Advisers sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2015, closing a stake of 35,583 shares — an estimated $348K sold.

Weiss Multi-Strategy Advisers first reported a position in CASC in Q3 2013 and held it in 7 quarters. The position peaked at $437K in Q4 2014. 100 funds tracked by Wall St. Rank hold CASC as of Q2 2015.

Weiss Multi-Strategy Advisers reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 35,583 Cascadian Therapeutics, Inc. shares in Q2 2015, an estimated $348K.
Weiss Multi-Strategy Advisers first reported a position in Cascadian Therapeutics, Inc. in Q3 2013 and held it in 7 quarters.
Weiss Multi-Strategy Advisers's Cascadian Therapeutics, Inc. position peaked at $437K in Q4 2014.
100 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2015.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2015, filed 14 Aug 2015.